| Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
 | Relative risk | 95 % Confidential interval | p | Relative risk | 95 % Confidential interval | p |
Age >60 years | 0.83 | 0.29–2.39 | 0.74 |  |  |  |
Male | 1.07 | 0.44–2.60 | 0.88 |  |  |  |
Diabetes mellitus | 1.53 | 0.76–3.062 | 0.23 |  |  |  |
Hypertension | 0.95 | 0.45–2.00 | 0.89 |  |  |  |
Dyslipidemia | 1.10 | 0.52–2.31 | 0.81 |  |  |  |
Current smoking | 1.32 | 0.64–2.71 | 0.45 |  |  |  |
Chronic renal insufficiency | 0.62 | 0.31–1.27 | 0.19 |  |  |  |
Previous PCI | 0.75 | 0.290–1.95 | 0.55 |  |  |  |
Previous myocardial infarction | 0.04 | 0.00–11.78 | 0.27 |  |  |  |
LAD vs LCx/RCA | 1.03 | 0.53–2.02 | 0.93 |  |  |  |
Stent diameter <3.0 mm | 1.33 | 0.66–2.67 | 0.43 |  |  |  |
Stented segment length > 15mm | 1.00 | 0.49–2.06 | 1.00 |  |  |  |
Aspirin | 21.14 | 0.00–159472.77 | 0.50 |  |  |  |
Clopidogrel | 1.38 | 0.48–3.93 | 0.55 |  |  |  |
ACE inhibitor / ARB | 0.98 | 0.42–2.26 | 0.98 |  |  |  |
Statins | 1.28 | 0.30–5.37 | 0.74 |  |  |  |
β-blockers | 0.50 | 0.25–1.00 | 0.05 | 0.56 | 0.28–1.13 | 0.11 |
FMD <4.2 % | 2.60 | 1.24–5.46 | 0.01 | 2.40 | 1.14–5.06 | 0.02 |